India Glycols Limited announced its audited standalone and consolidated financial results for the quarter and financial year ended March 31, 2026, during its board meeting held on May 14, 2026. The company reported a standalone revenue from operations of ₹2,361.40 Crores for Q4 FY26, representing an 8.11% increase compared to ₹2,188.00 Crores in the corresponding quarter of the previous year (YoY) but a decrease of 7.43% from ₹2,551.06 Crores in the preceding quarter (QoQ). Net profit for the current quarter stood at ₹65.25 Crores, showing a marginal growth of 1.48% YoY from ₹64.30 Crores, while decreasing by 4.38% QoQ from ₹68.24 Crores. At the same meeting, the Board of Directors approved the audited results and reviewed the overall performance for the fiscal year.

India Glycols Limited (IGL) is a leading Indian manufacturer of green technology-based chemicals, including bio-based specialties, performance chemicals, and natural gums. Established in 1988, the company operates across diverse segments such as potable spirits, industrial gases, and nutraceuticals. In 2025 and early 2026, IGL achieved several significant milestones, including receiving the Establishment Inspection Report (EIR) from the USFDA for its Dehradun nutraceuticals plant in April 2025, which facilitates exports to the US market. The company also focused on corporate restructuring, securing NCLT approval in April 2026 for a demerger scheme involving its Bio Pharma and Spirits businesses. Additionally, IGL declared an interim dividend of ₹7.50 per share in March 2026 and highlighted its first commercial sale of bio-based amines to L’Oreal as part of its strategic growth in green chemistry. The company maintains a strong promoter holding of approximately 59.63%, with institutional investors such as 360 One Pipe Fund holding notable stakes.